Cohen Circle Acquisition Corp. II Announces Pricing of $220,000,000 Initial Public Offering
The Company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business or industry or at any stage of its corporate evolution. The Company's primary focus, however, will be to identify companies in the financial services technology (fintech) sector and fintech adjacent sectors that power transformation and innovation. The management team is led by Betsy Z. Cohen, its Chief Executive Officer, Daniel G. Cohen, its Chairman of the Board of Directors, and Amanda J. Abrams, its Vice-Chairman of the Board of Directors.
Clear Street is serving as the sole book-running manager for the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 3,300,000 units at the initial public offering price to cover over-allotments, if any.
A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission on June 30, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Clear Street, Attn: Syndicate Department, 150 Greenwich Street, 45th floor, New York, NY 10007, by email at [email protected], or from the SEC website at www.sec.gov.
This press release contains statements that constitute 'forward-looking statements,' including with respect to the initial public offering. No assurance can be given that such offering will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the offering filed with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.
Contact Information:
Cohen Circle Acquisition Corp. II
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Apple stock surges despite analysts' concerns over AI strategy shift
-- Apple (NASDAQ:AAPL) stock rose 2% Tuesday, extending Monday's gains, following reports that the tech giant is considering using external AI technology to power its Siri voice assistant. According to Bloomberg, Apple has held discussions with both Anthropic and OpenAI about potentially leveraging their large language models for a new version of Siri. The company has reportedly asked these AI firms to train versions of their models that could run on Apple's cloud infrastructure for testing purposes. This marks a significant shift in Apple's AI strategy, as the iPhone maker currently relies on its in-house technology, called Apple Foundation Models, for most of its AI features. The company had been planning to develop a new version of Siri using this proprietary technology for 2026. Despite the stock's positive movement, some analysts view this potential strategy shift negatively. Lynx Equity Strategies analyst Kc Rajkumar suggested the news indicates Apple's AI team may be struggling with internal development. "AAPL stock's knee jerk reaction yesterday to the UPSIDE may have been premature. We think the implications of the media report are to the DOWNSIDE," Rajkumar noted. The analyst further explained that if Apple adopts OpenAI's technology, it might need to abandon plans to run its AI data centers on Apple silicon, potentially becoming a customer of NVIDIA (NASDAQ:NVDA) instead. This could significantly increase Apple's capital expenditures and impact its free cash flow, possibly affecting its stock buyback and dividend programs. Related articles Apple stock surges despite analysts' concerns over AI strategy shift Needham charts path for Taiwan Semi to generate $90B in AI revenue by 2030 Medical device makers stock falls after proposed Medicare payment cuts
Business Wire
12 minutes ago
- Business Wire
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the ' Securities Purchase Agreement ') with High Trail Special Situations LLC (' High Trail '), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000,000 in aggregate principal amount of unsecured convertible debentures (the ' Convertible Debentures '). The sale and issue of US$50,000,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the ' Private Placement '). The sale and issue of US$450,000,000 of the principal amount of Convertible Debentures will be determined at a future date, upon mutual agreement of the parties. 'This financing represents a major inflection point for Cybin and supports our position as a leader within our sector,' said Doug Drysdale, Chief Executive Officer of Cybin. "High Trail Capital is an experienced investor, and its confidence and appreciation of our breakthrough clinical data and intellectual property portfolio recognize the potential of the Company. This financing comes at an opportune time for Cybin, as we advance our lead programs, CYB003 and CYB004, in Phase 3 and Phase 2, respectively. CYB003 demonstrated over 70% remission rates and continued durability over 12 months for patients with uncontrolled depression. We await the conclusion of our CYB004 Phase 2 proof-of-concept study, in patients with generalized anxiety disorder,' said Drysdale. Joseph Gunnar & Co., LLC acted as the sole placement agent in connection with this transaction. Pipeline Acceleration Drives Multiple Value Creation Catalysts The funding will accelerate Cybin's clinical-stage programs across multiple high-value indications: CYB003 Program Achievements: Breakthrough Clinical Results: Unprecedented 71% remission rate in major depressive disorder at 12 months after two 16 mg doses in Phase 2 study Durability advantage: 12-month sustained efficacy demonstrating long-term therapeutic benefit FDA Recognition: Breakthrough Therapy Designation received, expediting regulatory pathway Multinational Phase 3 PARADIGM program underway CYB004 Program Momentum: Dual Indication Strategy: Expanding addressable market opportunity Phase 2 GAD study expected to complete around mid-year 2025 1 Commercialization Infrastructure: Manufacturing Scale-Up: Finalizing production capabilities for market launch IP Portfolio Expansion: Strengthening competitive moat with more than 90 patents issued and over 230 applications pending Strategic Partnerships: Developing market access and pre-commercialization alliances Value Catalysts Drive Sustained Momentum Near-Term Catalysts: CYB004 Phase 2 GAD study expected to complete around mid-2025 1 Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025 1 EXTEND study initiation imminent 1 Medium-Term Catalysts (2025-2026): Phase 3 top line readout for CYB003 2H 2026 1 Regulatory submission preparations Commercial manufacturing readiness International market expansion planning Transaction Terms The Convertible Debentures have a two-year term from the closing date (the ' Term '). The Company shall pay guaranteed interest equal to 5.5% of the principal per annum for the Term. Such interest was pre-paid on closing. Upon the occurrence of an event of default, interest shall increase to a rate of 18% per annum on the outstanding principal balance. Pursuant to the terms of the Securities Purchase Agreement, the Company and High Trail may, upon mutual consent, enter into subsequent securities purchase agreements for the purchase and sale of up to an additional US$450,000,000 principal amount of Convertible Debentures, in tranches, in amounts on such dates as may be mutually agreed and each subsequent tranche shall include prepaid interest at a rate of 9.5%. Subject to the terms of the Securities Purchase Agreement and the Convertible Debentures, High Trail will be entitled to convert the principal amount of, and accrued and unpaid interest, if any, on each Convertible Debenture, in whole or in part, from time to time, into common shares in the capital of the Company (the ' Common Shares ') at a conversion price per Common Share equal to the lower of (a) 130% of the volume weighted average price (' VWAP ') of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the five trading days immediately prior to the date of conversion. The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice prior to such prepayment. The prepayment shall include, (i) if paid during the first year after closing, a 5% prepayment premium on the amount of the prepayment or (ii) if paid thereafter, a 3% prepayment premium on the amount of the prepayment. The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to such conversion. The Company intends to use the net proceeds from the Private Placement for working capital and general corporate purposes. The Convertible Debentures were offered on a private placement basis pursuant to prospectus exemptions in Canada and pursuant to exemptions and exclusions from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws. The Company has agreed to use commercially reasonable efforts to: (a) file a prospectus supplement to the Company's base shelf prospectus dated August 17, 2023, as amended on December 22, 2023, April 8, 2024 and January 6, 2025, with applicable Canadian securities regulators to qualify the secondary market sales of the Common Shares in the United States; and (b) either (i) prepare and file the Canadian prospectus supplement with the United States Securities and Exchange Commission, or (ii) file a prospectus supplement pursuant to General Instruction II.L of Form F-10 with the United States Securities and Exchange Commission to the Company's registration statement on Form F-10 (File No. 333-284173), which was declared effective by the SEC on January 14, 2025, or on such other form as may be available to the Company, in either case qualifying the resale of the Common Shares underlying the Convertible Debentures. No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Notes: There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Cautionary Notes and Forward-Looking Statements Certain statements in this news release constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (together, 'forward-looking statements'). Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the use of Private Placement proceeds; the conversion of the Convertible Debentures into Common Shares; the sale and issue of US$450,000,000 principal amount of Convertible Debentures at a future date; CYB004 Phase 2 GAD study expected to complete around mid-2025; Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025; the Company's Medium-Term Catalysts for 2025-2026; Phase 3 PARADIGM program enrollment acceleration; the Company's ability to achieve commercial success; and the Company's ability to address the need for new and innovative treatment options for people who suffer from mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on and with the SEC on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Yahoo
13 minutes ago
- Yahoo
What Did US Stock Indexes Tell Us at the End of Q2?
US stock indexes found renewed buying interest 2025 Q2, the three major markets giving us 3 different technical reads. This raises the question of if technical analysis is useful in this day and age of algorithm driven trade and investments. Elon Musk's Tesla Makes History With 'First Time That a Car Has Delivered Itself to Its Owner' This Defense Stock Could Be the Next Palantir. Should You Buy It Now? Cathie Wood Is Pounding the Table on AMD Stock. Should You Buy Shares Now? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Is something as simple as the old Eyeball Test more valuable when fundamentals are hard to put a finger on? As June came to an end, also marking the end of Q2 for the Financials sector, the three major US stock index were giving different long-term reads from a technical analysis point of view. How do we know which to go with? Additionally, the bigger question is if technical analysis even matters anymore? Did it ever? If we apply my Market Rule #6 that says, 'Fundamentals win in the end', what fundamentals drive not only US but global stock markets? It's a lot to think about as we make our way to the next US holiday weekend. Let's start with long-term monthly charts in general. While I sill view the Nasdaq ($NASX) as a toss-up, I could still make the argument its long-term trend is up, again from a technical point of view. The Index completed a bullish spike reversal (new low for the selloff before rallying to close higher for the month) at the end of April before extending its rally to a new all-time high of 20,418.31 in late June. As a friend in the brokerage industry says, 'New highs are not bearish', and in the case of the Nasdaq (high tech stocks) that seems to be the case. What might the fundamental catalyst be for the rally? We know the US president has backed off his talk of tariffs on computer chips and electronics, though we'll soon find out if those threats come back up like convenience store sushi. My guess is they will, but time will tell. On the other hand, I still see the Dow Jones Industrial Average ($DOWI) in a long-term downtrend despite a second consecutive higher monthly settlement at the end of June. The key is a couple technical differences between the Nasdaq and the Dow: First, the latter did not complete a bullish spike reversal at the end of April. After falling to a low of 36,611.78 that month, its lowest level since October 2023 and within sight of the bearish 20% retracement mark of 36,058.90, the Dow rallied to close April at 40,669.36, still down 1,332.40 (3.2%) for the month. Given this, if we apply basic Elliott Wave technical analysis the initial selloff could be viewed as Wave A (first wave) of a 3-wave downtrend that began with the bearish 2-month reversal at the end of December 2024. If so, then the rally the index is posting now would be considered Wave B (second wave of 3). This brings up an interesting technical feature. Wave B, 'Depending on the type of correction[i]taking place, the rally may test the old highs (forming a double top) or even exceed the old highs before turning back down.'[ii] Given this definition, the key price is the all-time high of 45,073.63 from last December. Or is it? Despite the fact the S&P 500 Index ($INX) also hit a new all-time high in late June, reaching 6,215.08 before closing at 6,204.95, it could still be argued the index remains in a downtrend that began with the bearish spike reversal completed during February 2025 and confirmed with a new 4-month low during March. How is that possible? From a technical point of view, similar to the Dow the S&P 500 DID NOT complete a bullish spike reversal this past April. After falling to a low of 4,835.04, actually dipping below its bearish 20% retracement level of 4,917.94, the index closed at 5,569.06, down 42.79 (0.8%) for the month. However, as mentioned, the index has since rocketed to a new all-time high. Doesn't that automatically, mean the long-term trend has turned up? Not necessarily. Look back at the definition of Wave B, particularly the part that reads: '…the rally may test the old highs (forming a double top) or EVEN EXCEED THE OLD HIGHS (emphasis mine) before turning back down.' How do we know if the long-term trend is up or down? Let's apply a couple other ideas: If we bring the Horseshoe Proximity into play, we could say the April close was 'close enough' to completing a bullish spike reversal to count. Therefore, the index could be considered in a long-term uptrend, similar to the Nasdaq. If we apply the Benjamin Franklin Fish Analogy that tell us, 'Like guests and fish, markets start to stink after three days/weeks/months (whatever timeframe is being studied) of moving against the trend', we see the S&P 500, like the Dow (still in a downtrend) has posted two consecutive higher monthly closes (or three if we count April) within a downtrend meaning the index should soon turn back down. That didn't help at all, did it? In the end it comes down to applying the eyeball test, and the wisdom of my friend: New highs are not bearish. I'll accept this for now, but continue to be aware if something starts to smell fishy. [i] An analytical word I do not like, but it is in the book. [ii] From Technical Analysis of the Futures Market by John J. Murphy, 1986 edition, pg. 379 On the date of publication, Darin Newsom did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
